Geopolitical disruption and war-related cost inflation
Ongoing geopolitical situation has started impacting operating expenses; if prolonged, could pressure margins.
medium · management_commentary
Cipla Ltd — Q4 FY26
Cipla delivered a strong Q4 FY26 with India business growing 15% YoY and North America revenue of $155M.
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Lanreotide supply disruption and remediation uncertainty
Lanreotide remains off market due to partner remediation; timeline for return is uncertain, with alternate supplier filing expected by Q4 FY27.
high · analyst_questionIndore facility regulatory overhang
Indore site still under regulatory scrutiny; while most filings shifted to US/Goa, any adverse outcome could delay future filings.
medium · analyst_questionExecution risk in US respiratory launches
Achieving $1B run-rate depends on timely approvals and commercial execution of 4 respiratory assets; any delay could impact guidance.
medium · data_observation